Life Sciences Regulatory Compliance in Europe: 2026 Guide

By mid-2026, the European Commission's own survey of the 53 Notified Bodies designated under the Medical Devices Regulation shows 33,175 MDR applications submitted against only 17,549 certificates issued, with the gap for in vitro diagnostics proportionally wider still. The average review now runs 13 to 18 months, and at the most in-demand bodies the total wait, intake queue included, stretches to 19 to 30 months. Manufacturers filing today should not expect a certificate before late 2027. That backlog sits on top of a legislative overhaul the Commission proposed on 16 December 2025, a pharmaceutical reform that cleared its final trilogue the same month, and a UK reform track moving in a direction the EU never chose.

None of these four processes, the MDR/IVDR simplification proposal, the notified body capacity crisis, the EU pharmaceutical legislation recast, and the UK's post-Brexit medtech pathway, move on the same calendar. A compliance team tracking Europe in 2026 is not managing one regulatory reform. It is managing four, each with its own institutions, its own transition dates, and its own risk of a filing built on an assumption that changed months earlier.

Which regulators actually drive life sciences enforcement in Europe?

The European Medicines Agency authorizes centralized medicinal products, but medical devices and IVDs are certified by Notified Bodies acting under Commission oversight, coordinated through the Medical Device Coordination Group. National competent authorities, Germany's BfArM, France's ANSM, Ireland's HPRA, still run vigilance and market surveillance, while post-Brexit Great Britain answers to the Medicines and Healthcare products Regulatory Agency and Switzerland to Swissmedic, both now operating outside the EU's mutual recognition perimeter for devices. A company selling a diagnostic across the EU, UK and Switzerland is coordinating with at least four separate regulatory systems for what used to be treated as one CE-marked product.

What does the Commission's December 2025 MDR and IVDR simplification proposal actually change?

On 16 December 2025, the Commission adopted COM(2025) 1023, a targeted proposal amending Regulations (EU) 2017/745 and 2017/746 rather than replacing them. The proposal responds to an October 2024 European Parliament resolution and a 2025 Commission consultation that found the current framework created unnecessary cost, administrative bottlenecks, and delays in patient access. Its core measures include indefinite certificate validity for most device categories instead of the current fixed renewal cycle, a priority review track for orphan and breakthrough devices building on the MDCG 2025-9 guidance on breakthrough device criteria, and simplified requirements for in-house IVDs manufactured and used within the same health institution.

The proposal has been submitted to the European Parliament and Council for ordinary legislative procedure, and adoption is not expected before Q2 2027. Compliance teams building 2026 to 2028 product roadmaps around expectations of indefinite certificate validity are planning around a text that has not been adopted and could still be amended in trilogue. Treating this proposal as settled law before formal adoption is one of the most common near-term planning errors in the sector right now.

How bad is the Notified Body capacity crisis, and what is actually being done about it?

The Commission's 19th Notified Body survey, covering data through December 2025, confirms the bottleneck is structural rather than temporary: an 8% decline in qualified NB assessors year over year means the gap between applications and certifications is unlikely to close meaningfully before 2028. A near-term deadline compounds the pressure. Conformity assessment applications for Class C IVDs still certified under legacy IVDD rules had to reach a Notified Body by 26 May 2026, with a signed agreement due by 26 September 2026, or the product risks losing legal EU market access altogether.

The Commission's structural response is Implementing Regulation (EU) 2026/977, adopted 4 May 2026 and entering into force 25 May 2026. It sets binding maximum timelines, 30 days for application review and contract signature, 120 days for QMS auditing, 90 days for technical documentation assessment, and 20 days to issue the certificate after final review, alongside limits on the number of clarification "interruptions" a Notified Body can impose and a mandatory annual public report on median duration and cost per Notified Body. Critically, most of these obligations only apply from 25 February 2027, and only to agreements signed on or after that date; certificates already under review, or renewals of certificates expiring before 25 November 2027, fall outside the new regime entirely. A manufacturer negotiating a Notified Body contract in the second half of 2026 needs to know precisely which side of that line its agreement will fall on, since the protections do not apply retroactively.

What is the status of the EU pharmaceutical legislation reform, and when does it apply?

First proposed in April 2023 to replace Directive 2001/83/EC and Regulation (EC) No 726/2004, the pharmaceutical package reached provisional political agreement between the Council and Parliament on 11 December 2025. Coreper endorsed the compromise text on 6 March 2026, and the Parliament's SANT committee approved it on 18 March 2026. Formal adoption by both institutions is expected in autumn 2026, after which the acts enter into force and trigger a two-year transition period running to 2028, during which every member state must update national law and the Commission must adopt implementing and delegated acts. The reform also makes targeted amendments to the Clinical Trials Regulation (EU) No 536/2014 and EMA's extended mandate under Regulation (EU) 2022/123, so clinical trial sponsors and device-drug combination product teams are affected even if they think of this as a "pharma-only" file.

Tracking a reform through provisional agreement, committee endorsement, plenary vote, publication, and a two-year national transposition window, across 27 member states, is exactly the kind of multi-stage, multi-institution process that is easy to lose track of between headlines. Obsidian's monitoring follows each legislative file at the institutional level, from Coreper endorsement to Official Journal publication, so a compliance team sees the actual procedural stage rather than reacting to a press release announcing a still-informal deal.

How is the UK's post-Brexit medtech framework diverging from the EU?

On 8 May 2026, the MHRA published the draft Medical Devices (Amendment) Regulations 2026 on the WTO notification portal, the most significant overhaul of the Great Britain framework since Brexit. Its centerpiece is the International Reliance Pathway, which lets manufacturers use existing device authorizations from Australia, Canada or the United States to obtain a Certificate of International Reliance for the Great Britain market, through three risk-tiered routes, without needing UKCA marking. The draft also makes Unique Device Identifiers mandatory, aligns IVD classification with IMDRF risk categories, and formalizes Predetermined Change Control Plans for AI-enabled and software devices. Adoption is expected in December 2026, core provisions take effect in June 2027, and the International Reliance Pathway itself is not expected to become operational until 2028.

The EU is deliberately excluded from that reliance pathway. CE-marked device recognition in Great Britain is being handled through a separate MHRA consultation that closed 10 April 2026, leaving manufacturers to track two distinct UK policy tracks, international reliance and CE-mark recognition, that will not resolve on the same timeline. A device authorized in the EU today gains nothing from the International Reliance Pathway; it still depends entirely on the outcome of the separate CE-recognition decision.

Where does the EU-Switzerland relationship on medical devices stand after the March 2026 signing?

Switzerland has been treated as a third country for medical devices since 26 May 2021 and for IVDs since 26 May 2022, after the EU declined to update the Mutual Recognition Agreement's device chapter to reflect the MDR. On 2 March 2026, the EU and Switzerland signed a broad bilateral package that includes an updated MRA Annex referencing the MDR and IVDR directly, intended to restore mutual recognition of conformity assessments once it takes effect. That signature is not entry into force. Ratification requires consent from the European Parliament and Council on the EU side, and in Switzerland a parliamentary vote with a likely public referendum, putting practical implementation no earlier than 2028.

Until then, every obligation from the third-country period stays in force: EU manufacturers still need a Swiss Authorised Representative, and from 1 July 2026 registration in Switzerland's swissdamed database becomes mandatory, with full compliance required by 31 December 2026. Manufacturers celebrating the March signing as resolving the CH-REP requirement are acting on a headline rather than the legal timeline underneath it.

What should a Europe life sciences compliance team prioritize through the rest of 2026?

Confirm exactly which side of the 25 February 2027 line each pending Notified Body agreement will fall on, since the new timeline protections in Regulation (EU) 2026/977 do not apply retroactively. Track the MDR/IVDR simplification proposal as a bill in progress, not adopted law, while planning device portfolios. Register in swissdamed before the 31 December 2026 compliance deadline regardless of the March 2026 MRA signing, and watch the MHRA's separate CE-recognition decision if UK market access depends on EU certification.

Four institutions, four legislative calendars, and a certification backlog measured in years is not a workload a spreadsheet or a single regulator's newsletter can keep current. Obsidian's AI companion answers a specific question, such as whether a Notified Body agreement signed today falls under the old or new timeline regime, directly against the verified regulatory records tracked throughout this article, and the same data is available programmatically through the MCP for teams building their own compliance tooling. See how Obsidian's plans map to jurisdiction-level monitoring for exactly the EU, UK and Swiss slices covered here.